The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

University of Electronic Science and Technology of China

Status: Completed

Conditions: Healthy

Treatments: Drug: Intranasal Placebo; Drug: Intranasal Vasopressin (AVP); Drug: Intranasal Oxytocin (IN-OXT)

Study type: Interventional

Funder types: Other

Identifiers

NCT06605300

UESTC-neuSCAN-96

Details and patient eligibility

About

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

Full description

A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.

Enrollment: 120 patients

Sex: All

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion criteria

• History of head injury.
• Pregnant,menstruating,taking oral contraceptives.
• Medical or psychiatric illness.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 3 patient groups, including a placebo group

oxytocin

Experimental group

Description:

A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril.

Treatment:

Drug: Intranasal Oxytocin (IN-OXT)

vasopressin

Experimental group

Description:

A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril.

Treatment:

Drug: Intranasal Vasopressin (AVP)

placebo

Placebo Comparator group

Description:

A single dose of placebo will be administered with 3 puffs of treatment to each nostril.

Treatment:

Drug: Intranasal Placebo